Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) working group provided updates at the GRAPPA 2024 annual meeting on their assessment of composite outcome measures for PsA. The group presented the progress of a systematic literature review on the psychometric properties of the following candidate composite outcome measures using the OMERACT filter 2.2: (1) minimal disease activity (MDA), (2) Disease Activity for Psoriatic Arthritis (DAPSA), (3) American College of Rheumatology (ACR) response criteria, (4) Psoriatic Arthritis Disease Activity Score (PASDAS), (5) Composite Psoriatic Disease Activity Index (CPDAI), (6) 3-item visual analog scale (3VAS), and (7) 4VAS. A Delphi exercise for patient research partners (PRPs) on domain match and feasibility is ongoing. Following analysis and endorsement of domain match and feasibility by PRPs, the working group will seek endorsement from the GRAPPA community. In addition, the group illustrated a new research proposal for using network metaanalysis to quantitatively compare the responsiveness of these various composite outcome measures.